|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-5-25
|
|
pubmed:abstractText |
Patients with inflammatory bowel disease (IBD) affecting the colon are at increased risk of developing colorectal cancer (CRC). Published data are conflicting about whether 5-aminosalicylic acid (5-ASA) has chemopreventive properties against IBD-related carcinogenesis. The objective of this observational study was to determine if an association between 5-ASA therapy and CRC risk exists in IBD patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0998
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-71
|
|
pubmed:meshHeading |
pubmed-meshheading:17206695-Aged,
pubmed-meshheading:17206695-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:17206695-Case-Control Studies,
pubmed-meshheading:17206695-Colorectal Neoplasms,
pubmed-meshheading:17206695-Female,
pubmed-meshheading:17206695-Humans,
pubmed-meshheading:17206695-Inflammatory Bowel Diseases,
pubmed-meshheading:17206695-Male,
pubmed-meshheading:17206695-Mesalamine,
pubmed-meshheading:17206695-Risk,
pubmed-meshheading:17206695-Sulfasalazine,
pubmed-meshheading:17206695-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
|
|
pubmed:affiliation |
University of California, San Francisco, San Francisco, California 94143-1623, USA. Jonathan.Terdiman@ucsf.edu
|
|
pubmed:publicationType |
Journal Article
|
